NO20061362L - Caspase-inhibitorer inneholdende en isoksazolinring - Google Patents
Caspase-inhibitorer inneholdende en isoksazolinringInfo
- Publication number
- NO20061362L NO20061362L NO20061362A NO20061362A NO20061362L NO 20061362 L NO20061362 L NO 20061362L NO 20061362 A NO20061362 A NO 20061362A NO 20061362 A NO20061362 A NO 20061362A NO 20061362 L NO20061362 L NO 20061362L
- Authority
- NO
- Norway
- Prior art keywords
- caspase inhibitors
- inhibitors containing
- isoxazoline ring
- isoxazoline
- ring
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Den foreliggende oppfinnelse vedrører et isoksazolin-derivat som en inhibitor mot forskjellige caspaser, en fremgangsmåte for fremstiUing av dette og en terapeutisk blanding for forhindring av inflammasjon og apoptose omfattende dette.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20030059451 | 2003-08-27 | ||
| PCT/KR2004/002139 WO2005021516A1 (en) | 2003-08-27 | 2004-08-26 | Caspase inhibitors containing isoxazoline ring |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20061362L true NO20061362L (no) | 2006-03-24 |
| NO335620B1 NO335620B1 (no) | 2015-01-12 |
Family
ID=36102769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20061362A NO335620B1 (no) | 2003-08-27 | 2006-03-24 | Caspaseinhibitorer, samt fremgangsmåte for fremstilling derav, terapeutisk blanding som inneholder nevnte inhibitor anvendelig ved forhindring av inflammasjon og apoptose. |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US7557133B2 (no) |
| EP (1) | EP1660464B1 (no) |
| JP (1) | JP4503017B2 (no) |
| KR (1) | KR100594544B1 (no) |
| CN (1) | CN1842521B (no) |
| AP (1) | AP2104A (no) |
| AR (1) | AR045503A1 (no) |
| BR (1) | BRPI0413848B8 (no) |
| CA (1) | CA2535711C (no) |
| EA (1) | EA012080B1 (no) |
| EC (1) | ECSP066378A (no) |
| EG (1) | EG25751A (no) |
| HK (1) | HK1092788A1 (no) |
| IL (1) | IL173638A (no) |
| MA (1) | MA27999A1 (no) |
| MX (1) | MXPA06002267A (no) |
| MY (1) | MY162110A (no) |
| NO (1) | NO335620B1 (no) |
| NZ (1) | NZ545216A (no) |
| OA (1) | OA13244A (no) |
| PE (1) | PE20050371A1 (no) |
| TR (1) | TR200600899T2 (no) |
| TW (1) | TWI346110B (no) |
| UA (1) | UA83240C2 (no) |
| UY (1) | UY28494A1 (no) |
| WO (1) | WO2005021516A1 (no) |
| ZA (1) | ZA200601586B (no) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100774999B1 (ko) * | 2005-02-26 | 2007-11-09 | 주식회사 엘지생명과학 | 이소옥사졸린 유도체 및 그의 제조 방법 |
| US7754909B1 (en) * | 2005-04-06 | 2010-07-13 | The Florida State University Research Foundation, Inc. | Compounds and methods of arylmethylation (benzylation) as protection for alcohol groups during chemical synthesis |
| KR101299720B1 (ko) * | 2006-08-16 | 2013-08-28 | 주식회사 엘지생명과학 | 3-아미노-5-플루오로-4-디알콕시펜탄산 에스테르의 새로운제조방법 |
| KR20080042290A (ko) * | 2006-11-09 | 2008-05-15 | 주식회사 엘지생명과학 | 피리돈 구조를 포함하는 캐스파제 저해제 |
| EP2186804B1 (en) * | 2007-08-10 | 2015-06-17 | Nippon Soda Co., Ltd. | Nitrogen-containing heterocyclic compound and pest control agent |
| KR20090099886A (ko) * | 2008-03-18 | 2009-09-23 | 주식회사 엘지생명과학 | 캐스파제 저해제의 프로드럭 |
| SG191591A1 (en) | 2008-05-21 | 2013-07-31 | New World Lab Inc | Selective caspase inhibitors and uses thereof |
| US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
| CA2831704C (en) | 2011-03-31 | 2019-10-01 | Bayer Intellectual Property Gmbh | Herbicidally and fungicidally active 3-phenylisoxazoline-5-carboxamides and 3-phenylisoxazoline-5-thioamides |
| DK2697246T3 (en) * | 2011-04-15 | 2018-05-28 | Genesis Tech Limited | SELECTIVE CYSTEIN PROTEASE INHIBITORS AND USES THEREOF |
| AU2013322855B2 (en) * | 2012-09-25 | 2017-06-22 | Bayer Cropscience Ag | Herbicidal and fungicidal 5-oxy-substituted 3-phenylisoxazoline-5-carboxamides and 5-oxy-substituted 3-phenylisoxazoline-5-thioamides |
| US9585392B2 (en) * | 2012-09-25 | 2017-03-07 | Bayer Cropscience Ag | 3-phenylisoxazolin derivatives with herbicidal action |
| EP2900660B1 (de) | 2012-09-25 | 2018-01-17 | Bayer CropScience AG | Herbizid und fungizid wirksame 3-heteroarylisoxazolin-5-carboxamide und 3- heteroarylisoxazolin-5-thioamide |
| JP2017095353A (ja) * | 2014-03-27 | 2017-06-01 | 日本曹達株式会社 | イソオキサゾリン−５−カルボキサミド化合物および有害生物防除剤 |
| BR112016026560A2 (pt) | 2014-05-12 | 2017-08-15 | Conatus Pharmaceuticals Inc | Método para tratar uma complicação de uma doença hepática crônica, método para tratar hipertensão portal, método para inibir uma cascata de sinalização de tnf-a e de a-fas; composição farmacêutica, kit, método de tratamento, método para tratar uma afecção |
| CN105753853B (zh) | 2014-12-16 | 2020-08-04 | 沈阳中化农药化工研发有限公司 | 一种含异恶唑啉的脲嘧啶类化合物及其用途 |
| WO2017079566A1 (en) | 2015-11-05 | 2017-05-11 | Conatus Pharmaceuticals, Inc. | Caspase inhibitors for use in the treatment of liver cancer |
| RU2018127752A (ru) | 2015-12-31 | 2020-01-31 | Конатус Фармасьютикалз Инк. | Способы применения ингибиторов каспаз при лечении заболеваний печени |
| KR20190062501A (ko) | 2016-10-05 | 2019-06-05 | 노파르티스 아게 | 섬유증, 간경화 질환 또는 질병을 치료 또는 예방하기 위한 fxr 작용제를 포함하는 조합 조성물 |
| US11434212B2 (en) * | 2017-01-23 | 2022-09-06 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Bicyclic compound as a caspase inhibitor |
| BR112019026261B1 (pt) | 2017-06-13 | 2023-12-19 | Bayer Cropscience Aktiengesellschaft | 3- fenilisoxazolina-5-carboxamidas e seus usos para controlar plantas indesejadas |
| PL3638666T3 (pl) | 2017-06-13 | 2022-01-03 | Bayer Aktiengesellschaft | Chwastobójczo skuteczne 3-fenyloizoksazolino-5-karboksyamidy amidów kwasu tetrahydro- i dihydrofuranokarboksylowego |
| WO2019034602A1 (de) | 2017-08-17 | 2019-02-21 | Bayer Aktiengesellschaft | Herbizid wirksame 3-phenyl-5-trifluormethylisoxazolin-5-carboxamide von cyclopentylcarbonsäuren und -estern |
| EA202091774A1 (ru) | 2018-01-25 | 2020-12-07 | Байер Акциенгезельшафт | Гербицидно-активные 3-фенилизоксазолин-5-карбоксамиды производных циклопентенилкарбоновой кислоты |
| EP3937637B1 (de) | 2019-03-12 | 2023-04-19 | Bayer Aktiengesellschaft | Herbizid wirksame 3-phenylisoxazolin-5-carboxamide von s-haltigen cyclopentenylcarbonsäureestern |
| EP3939976B1 (en) * | 2019-04-19 | 2024-05-01 | Lg Chem, Ltd. | Prodrug of caspase inhibitor |
| US20220227743A1 (en) * | 2019-04-30 | 2022-07-21 | Lg Chem, Ltd. | Prodrug of caspase inhibitor |
| TW202237143A (zh) | 2020-12-10 | 2022-10-01 | 南韓商Ｌｇ化學股份有限公司 | 酸（Ｂｏｒｏｎｉｃ Ａｃｉｄ）化合物 |
| WO2022123062A1 (en) | 2020-12-11 | 2022-06-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Blocking caspase and/or fasl for preventing fatal outcome in covid-19 patients |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2738486B2 (ja) | 1992-11-20 | 1998-04-08 | ファイザー製薬株式会社 | 抗炎症剤としての新規なイソオキサゾリン類 |
| WO1995014681A1 (en) * | 1993-11-26 | 1995-06-01 | Pfizer Inc. | Isoxazoline compounds as antiinflammatory agents |
| ATE187447T1 (de) * | 1993-11-26 | 1999-12-15 | Pfizer | 3-phenyl-2-isoxazoline derivate als entzündugshemmende mittel |
| US5710159A (en) * | 1996-05-09 | 1998-01-20 | The Dupont Merck Pharmaceutical Company | Integrin receptor antagonists |
| IL118325A0 (en) * | 1995-05-25 | 1996-10-31 | Pont Merck And Pharmaceutical | Integrin receptor antagonists and pharmaceutical compositions containing them |
| KR100373375B1 (ko) * | 1998-04-03 | 2003-06-12 | 주식회사 엘지생명과학 | 인터루킨-1b-컨버팅효소및아포파인/cpp-32에대한저해제 |
| AU5762899A (en) * | 1999-09-17 | 2001-04-24 | Lg Chemical Ltd. | Caspase inhibitor |
| DE60013147T2 (de) | 1999-09-17 | 2005-08-11 | Lg Chem Investment, Ltd. | Caspase-hemmer |
-
2004
- 2004-08-24 KR KR1020040066726A patent/KR100594544B1/ko active IP Right Grant
- 2004-08-26 US US10/568,503 patent/US7557133B2/en active Active
- 2004-08-26 EP EP04774400.8A patent/EP1660464B1/en active Active
- 2004-08-26 BR BRPI0413848A patent/BRPI0413848B8/pt active IP Right Grant
- 2004-08-26 MX MXPA06002267A patent/MXPA06002267A/es active IP Right Grant
- 2004-08-26 JP JP2006524573A patent/JP4503017B2/ja active Active
- 2004-08-26 NZ NZ545216A patent/NZ545216A/en unknown
- 2004-08-26 CA CA2535711A patent/CA2535711C/en active Active
- 2004-08-26 AR ARP040103065A patent/AR045503A1/es active IP Right Grant
- 2004-08-26 UA UAA200602050A patent/UA83240C2/ru unknown
- 2004-08-26 EG EG2004080370A patent/EG25751A/xx active
- 2004-08-26 CN CN2004800247028A patent/CN1842521B/zh active Active
- 2004-08-26 EA EA200600465A patent/EA012080B1/ru not_active IP Right Cessation
- 2004-08-26 MY MYPI20043481A patent/MY162110A/en unknown
- 2004-08-26 OA OA1200600061A patent/OA13244A/en unknown
- 2004-08-26 WO PCT/KR2004/002139 patent/WO2005021516A1/en active Application Filing
- 2004-08-26 TW TW093125466A patent/TWI346110B/zh active
- 2004-08-26 AP AP2006003509A patent/AP2104A/en active
- 2004-08-26 TR TR2006/00899T patent/TR200600899T2/xx unknown
- 2004-08-27 UY UY28494A patent/UY28494A1/es active IP Right Grant
- 2004-08-27 PE PE2004000822A patent/PE20050371A1/es active IP Right Grant
-
2006
- 2006-02-09 IL IL173638A patent/IL173638A/en active IP Right Grant
- 2006-02-15 EC EC2006006378A patent/ECSP066378A/es unknown
- 2006-02-17 MA MA28820A patent/MA27999A1/fr unknown
- 2006-02-23 ZA ZA200601586A patent/ZA200601586B/en unknown
- 2006-03-24 NO NO20061362A patent/NO335620B1/no unknown
- 2006-09-08 HK HK06110041.2A patent/HK1092788A1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20061362L (no) | Caspase-inhibitorer inneholdende en isoksazolinring | |
| DK1206474T3 (da) | Sulfonylphenylpyrazolforbindelser anvendelige som cox-2-inhibitorer | |
| NO20061627L (no) | Haloalkyl inneholdende forbindelser som cysteinproteaseinhibitorer | |
| EA200900802A1 (ru) | Способы и композиции для лечения амилоидных заболеваний | |
| ECSP045429A (es) | Combinacion de compuestos organicos | |
| NO20044731L (no) | Kinolin- og isokinolinderivater fremgangsmate for fremstilling derav og anvendelse derav som betennelseshemmere | |
| EA200600078A1 (ru) | Способы и композиции для лечения амилоидных заболеваний | |
| NO20071078L (no) | Antivirale forbindelser | |
| NO20070866L (no) | Antivirale forbindelser. | |
| NO20050525L (no) | Benzimidazol-1-yl-tiofenforbindelser for behandling av cancer | |
| HUP0301660A2 (hu) | Neutrális endropeptidáz inhibitor (NEPI) vegyületek alkalmazása férfi szexuális mżködési zavar kezelésére és az azokat tartalmazó gyógyszerkészítmények | |
| EA200500203A1 (ru) | Новый способ синтеза и новая кристаллическая форма агомелатина и фармацевтические композиции, которые её содержат | |
| NO20054880L (no) | Azaspiroalkanderivater som inhibitorer av metallproeaser | |
| CR7333A (es) | Forma poliforma de rimonabant, su procedimiento de preparacion y composiciones farmaceuticas que la contienen | |
| NO20062021L (no) | Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika | |
| IN2005KO00312A (no) | ||
| TNSN06138A1 (fr) | Inhibitors of the mutant form of kit | |
| MXPA05012837A (es) | Inhibidores de caspasa y usos de los mismos. | |
| DK1641803T3 (da) | Thienopyrimidinderivater som kaliumkanalinhibitorer | |
| NO20055612L (no) | Anti-inflammatoriske fosfonatforbindelser | |
| DK1339407T3 (da) | Farnesylproteintransferaseinhibitorer til behandling af inflammatorisk tarmsygdom | |
| NO20072258L (no) | Farmasøytiske sammensetninger omfattende et camptothecinderivat | |
| HN2003000063A (es) | Derivados de nicotinamida y una sal de tiotropio en combinacion para el tratamiento de enfermedades. | |
| DK1448562T3 (da) | Substituerede tetracycliske pyrroloquinolonderivater egnede som phosphodiesteraseinhibitorer | |
| WO2006034391A3 (en) | Indole inhibitors of 15-lipoxygenase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: LG CHEM, KR |